Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q4 FY23 results · Jan–Mar 2023
Ajanta Pharma reported revenue from operations of ₹881.84 crore (up 1.3% from Q4 FY22) and net profit of ₹122.25 crore (down 19.2% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 881.84 | 870.29 | +1.3% | 971.77 | −9.3% |
| Other income | 36.83 | 29.48 | +24.9% | 34.93 | +5.4% |
| Total income | 918.67 | 899.77 | +2.1% | 1,006.70 | −8.7% |
| Profit before tax | 152.05 | 197.67 | −23.1% | 168.34 | −9.7% |
| Net profit for the period | 122.25 | 151.21 | −19.2% | 134.51 | −9.1% |
| EPS, basic (₹) | 9.54 | 17.70 | not comparable | 10.50 | −9.1% |
| Net margin (%) | 13.9 | 17.4 | 13.8 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 848.86 | 765.63 | +10.9% | 874.89 | −3.0% |
| Other income | 36.75 | 28.42 | +29.3% | 30.51 | +20.5% |
| Total income | 885.61 | 794.05 | +11.5% | 905.40 | −2.2% |
| Profit before tax | 147.96 | 178.30 | −17.0% | 154.95 | −4.5% |
| Net profit for the period | 117.21 | 134.84 | −13.1% | 123.96 | −5.4% |
| EPS, basic (₹) | 9.15 | 15.79 | not comparable | 9.67 | −5.4% |
| Net margin (%) | 13.8 | 17.6 | 14.2 |
Consolidated
- Filed with BSE
- 08 May 2023, 17:50 IST
- Board meeting
- 05 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 May 2023, 17:50 IST
- Board meeting
- 05 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE